Successful heartworm treatment requires far more than eliminating adult worms.
Tom Nelson, DVM
Research Committee Chair
American Heartworm Society
Heartworm treatment requires an understanding of the distinction between heartworm infection and heartworm disease. Heartworm infection refers to the presence of tissue-phase larvae together with immature and mature adult worms within the pulmonary vasculature. Heartworm disease, in contrast, refers to the pathological changes produced by that infection. Although treatment can eliminate the parasite, much of the vascular and pulmonary damage is irreversible. Consequently, the primary objective of therapy is not simply to eliminate heartworms but to minimize additional pulmonary injury during treatment.
Pathogenesis of Heartworm Disease
Heartworms produce extensive pathological changes throughout the pulmonary arterial system. Live adult worms residing in the main pulmonary arteries, lobar arteries, and their branches repeatedly traumatize the endothelial lining as they are continuously moved back and forth by blood flow. This chronic mechanical injury results in villous endarteritis, hypertrophy of the arterial walls, fibrosis, and progressive loss of vascular elasticity, ultimately increasing pulmonary vascular resistance.
As heartworms die, either naturally or following adulticidal therapy, they collapse and are carried by blood flow into the segmental branches of the lobar arteries. The dead worms, together with the resulting inflammatory response, platelet aggregation, and fibrin deposition, produce pulmonary thromboembolic disease. These processes further increase fibrosis and vascular resistance.
Inflammatory mediators released during this process are carried downstream to the pulmonary capillary beds and alveoli, where they cause edema of the type I alveolar epithelial cells, rendering them fragile and prone to rupture. During periods of increased activity or exercise, the accompanying increases in pulmonary blood flow and ventilation can cause these weakened alveolar-capillary units to rupture. A dry, hacking cough, with or without hemoptysis, is a common consequence. The affected alveoli subsequently fill with blood, followed by fibrin deposition and additional fibrosis.
Over time, progressive fibrosis, pulmonary thromboembolism, and loss of vascular elasticity increasingly restrict pulmonary blood flow and elevate pulmonary vascular resistance. As pulmonary arterial pressure rises, pulmonary hypertension develops and may eventually progress to right-sided heart failure. In severe infections, adult worms may have retrograde movement into the right ventricle, resulting in caval syndrome.
Understanding these pathological processes explains why successful treatment must focus not only on eliminating adult heartworms but also on minimizing the pulmonary injury associated with their death.
Principles of Treatment
Eliminating adult heartworms is relatively straightforward. Preventing the pulmonary injury that accompanies worm death is considerably more challenging and should be the primary focus of treatment. Adult worms may be eliminated rapidly with melarsomine or gradually using so-called "slow-kill" protocols; however, the manner and timing of worm death largely determine the severity of post-treatment pulmonary pathology.
Fast-kill protocols consist of two or three melarsomine injections, eliminating approximately 90% and 99% of adult worms, respectively within 1-2 months. Slow-kill protocols combine doxycycline with monthly administration of a macrocyclic lactone, resulting in gradual worm death over approximately 9–18 months. Regardless of the protocol employed, pulmonary injury results primarily from worm death rather than from the drug itself.
Every component of the treatment protocol recommended by the American Heartworm Society (AHS) is designed to maximize efficacy while minimizing the inflammatory and thromboembolic complications associated with adult worm death.
Phase One: Heartworm Preventive and Doxycycline. The first phase of the AHS protocol begins by administering a heartworm preventive, if the dog is not already receiving one, to prevent additional infections.
Doxycycline is then administered at 10 mg/kg twice daily for four weeks to reduce Wolbachia, the rickettsial endosymbiont present in all life stages of Dirofilaria immitis. Depletion of Wolbachia and its surface proteins (WSP) significantly reduces the inflammatory response that follows adult worm death. A subsequent one-month waiting period allows further reduction of WSP before adulticide therapy begins.
Doxycycline may cause vomiting and diarrhea in some dogs. These adverse effects can often be minimized by administering the medication with food. If gastrointestinal signs occur, treatment should be discontinued until they resolve and then restarted at a reduced dosage of 7.5 mg/kg twice daily. If intolerance persists, the dosage may be further reduced to 5 mg/kg twice daily. Although lower dosages are less effective than the recommended regimen, they still substantially reduce Wolbachia populations and WSP concentrations, particularly when followed by the one-month waiting period. Any doxycycline is preferable to none, although 5 mg/kg twice daily for two weeks should be considered the minimum acceptable regimen.
Approximately 40% of dogs receiving doxycycline develop elevated liver enzyme activities. As long as the patient remains clinically normal and maintains a normal appetite, these elevations are generally not clinically significant and resolve after treatment is completed.
Beyond its antimicrobial effects, doxycycline possesses anti-inflammatory and immunomodulatory properties that help reduce pulmonary inflammation. At higher tissue concentrations, it also inhibits protein synthesis in mammalian cells, which may contribute to reduced fibrosis. A small subset of dogs cannot tolerate doxycycline at any dosage. In these patients, rifampin may be considered as an alternative because it also depletes Wolbachia, although it lacks many of doxycycline's additional anti-inflammatory benefits.
Phase Two: Three-Dose Melarsomine Therapy. Following the one-month waiting period, the first melarsomine injection is administered. This initial dose eliminates approximately 50% of the adult worms. Because the actual worm burden cannot be accurately determined, this staged approach minimizes post-treatment complications in heavily infected dogs while providing the highest overall efficacy.
Prednisone is administered concurrently in a tapering regimen because it reduces edema of the type I alveolar epithelial cells, thereby decreasing their fragility. Strict exercise restriction is also instituted because increased pulmonary blood flow during activity promotes rupture of these damaged alveolar-capillary units.
Prednisone may be contraindicated in some patients, such as those with diabetes mellitus, and a small number of dogs develop unacceptable behavioral changes while receiving corticosteroids. In these situations, an NSAID may be considered. Although there is no evidence that NSAIDs provide the same protection against pulmonary injury, they may offer some anti-inflammatory benefit.
The second and third melarsomine injections are administered one month after the first injection and should be given within 24 hours of one another at the recommended dosage of 2.5 mg/kg. Reducing the dosage of any melarsomine injection or extending the interval between the second and third injections significantly decreases treatment efficacy.
Despite appropriate use of doxycycline, prednisone, and staged melarsomine therapy, some dogs with heavy worm burdens will still develop clinical pulmonary thromboembolic disease. If this occurs after the first melarsomine injection, the interval before administering the second and third injections may be extended for as long as six months to allow clinical signs to resolve.
Melarsomine is eliminated from the body within approximately six hours. Injection-site soreness is the most common adverse effect and is usually related to injection technique. Respiratory complications are the next most common problem and result from worm death rather than drug toxicity. Adherence to the AHS protocol reduces these complications from approximately 22% to about 6%. In extremely rare cases, dogs may experience an anaphylactoid reaction following melarsomine administration. If this occurs, a slow-kill protocol should be considered.
Exercise Restriction
Strict exercise restriction is essential regardless of the treatment protocol. Exercise increases pulmonary blood flow and vascular pressure, promoting rupture of damaged alveolar-capillary units and worsening pulmonary thromboembolism. The American Heartworm Society recommends restricting activity for approximately four to five months during adulticide therapy.
Following these recommendations reduces respiratory complications to approximately 6%, with a mortality rate of less than 1%. In contrast, slow-kill protocols require 9–18 months for adult worm death, making prolonged exercise restriction impractical and likely contributing to reported respiratory complication rates of 25–36%.
Although worm death during melarsomine therapy occurs primarily within the two months following treatment, the timing of worm death during slow-kill protocols remains poorly defined. Because long-term exercise restriction and prolonged anti-inflammatory prednisone therapy are impractical, the higher rate of pulmonary complications associated with slow-kill treatment is not surprising. Coughing remains the principal respiratory complication and serves as a clinical indicator of ongoing pulmonary injury. In general, more coughing reflects greater pulmonary pathology and more permanent lung damage.
Management of Advanced Heartworm Disease
Even dogs with advanced heartworm disease can often be successfully treated if cardiovascular complications are stabilized before adulticide therapy begins. Dogs with ascites may benefit from abdominocentesis to relieve diaphragmatic compression, followed by appropriate medical management with sildenafil, pimobendan, ACE inhibitors, and furosemide. The first phase of the AHS protocol can be initiated concurrently while right-sided heart failure is being stabilized.
Once heart failure is adequately controlled, the three-dose melarsomine protocol can proceed. In some patients, delaying the second and third injections for two to three months after the initial injection may allow sufficient resolution of pulmonary inflammation before completing treatment. If right-sided heart failure cannot be medically controlled, adulticidal therapy is unlikely to succeed, and surgical worm extraction should be considered the preferred treatment option.
Conclusion
Successful heartworm treatment requires far more than eliminating adult worms. The primary objectives are to minimize pulmonary injury and preserve long-term cardiopulmonary function. The American Heartworm Society protocol accomplishes this by combining Wolbachia depletion, staged adulticide therapy, corticosteroid administration, and strict exercise restriction to reduce the inflammatory and thromboembolic consequences of worm death. When carefully followed, this protocol provides the highest cure rate while minimizing permanent pulmonary damage and treatment-related complications.
